| Targeting Inflammation and Oxidative Stress to Treat Acute Lung Injury With CNP-miR146a |
Grant |
124,792.00 |
Research |
Geoffrey Gurtner |
Surgery |
05/2024 |
| Targeting P53-Mutated Head and Neck Squamous Cell Carcinoma |
Grant |
749,993.00 |
Research |
Carlos Caulin |
Otolaryngology |
05/2024 |
| The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF) |
Cooperative Agreement |
29,876.00 |
Research |
Roderick Tung |
COM Phx Internal Medicine |
05/2024 |
| University of Arizona - Title V Needs Assessment |
Contract |
232,000.00 |
Other Sponsored Activity |
John Ehiri |
Public Health Administration |
05/2024 |
| A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527 |
Contract |
348,649.08 |
Clinical Trial |
Jennifer Segar |
Cancer Center Division |
04/2024 |
| A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects |
Contract |
303,564.48 |
Clinical Trial |
Scott Sherman |
Neurology |
04/2024 |
| A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety,Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab |
Contract |
20,590.00 |
Clinical Trial |
Rachna Shroff |
Cancer Center Division |
04/2024 |
| A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen |
Contract |
19,770.00 |
Clinical Trial |
David Labiner |
Neurology |
04/2024 |
| A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients |
Contract |
23,990.00 |
Clinical Trial |
Aaron Scott |
Cancer Center Division |
04/2024 |
| A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associate |
Contract |
270,564.00 |
Clinical Trial |
Sachin Chaudhary |
Medicine |
04/2024 |
| A Prospective, Open Label, Single-Arm, Multi-Center Study Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment Of Osteochondral Lesions in the Knee |
Contract |
179,695.68 |
Clinical Trial |
Thomas Carter |
COM Phx Orthopedics |
04/2024 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Act |
Contract |
133,337.00 |
Clinical Trial |
Sasha Taleban |
Medicine |
04/2024 |
| A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled,Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esopha |
Contract |
2,600.00 |
Clinical Trial |
Geoffrey Block |
Liver Research Institute |
04/2024 |
| Advanced Methods and Software for Trial Sequential Analysis in Living Systematic Reviews |
Grant |
364,114.00 |
Research |
Lifeng Lin |
Epidemiology and Biostatistics |
04/2024 |
| Biological Function and Regulation of PRMT9 in Synapse Development |
Grant |
128,937.00 |
Research |
Shenfeng Qiu |
COM Phx Basic Medical Sci |
04/2024 |
| Computer Modeling of Myosin Binding Protein C and Its Effects on Cardiac Contraction |
Grant |
126,750.00 |
Research |
Brett Colson |
Cellular & Molecular Medicine |
04/2024 |
| Connexins as Potential Biomarkers and Therapeutic Targets for Vascular Malformation |
Grant |
15,299.00 |
Research |
Jose Ek Vitorin |
Physiology |
04/2024 |
| Deep-Learning Based Pharmacokinetic Model for Vancomycin |
Grant |
29,054.00 |
Research |
Bijun Kannadath |
COM Phx Internal Medicine |
04/2024 |
| Developing Personalized Ovarian Cancer Risk Prediction through Circulating miRNA Biomarkers in 'Non-Genetic High-Risk' Women |
Grant |
750,000.00 |
Research |
Setsuko Chambers |
Obstetrics and Gynecology |
04/2024 |
| Disrupted Lipid Metabolism in Alzheimer's Disease |
Grant |
1,610,885.00 |
Research |
Fei Yin |
UAHS Brain Science |
04/2024 |
